Tenofovir disoproxil

Generic Name: Tenofovir disoproxil

Brand Names: Atripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Truvada, Viread, Tenofovir disoproxil Mylan

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₃₀N_₅O_₁₀P

CAS Number: 201341-05-1

Unique Ingredient Identifier: F4YU4LON7I

Background: Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug is prescribed in combination with other drugs for the management of HIV infection as well as for Hepatitis B therapy. Tenofovir disoproxil was initially approved in 2001 .

Indication: Tenofovir disoproxil is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients ≥2 years old and weighing ≥10 kg. It is also indicated for the treatment of chronic hepatitis B in patients ≥2 years old and weighing ≥10 kg.

Tenofovir disoproxil is also an ingredient in several combination products, all of which are indicated either alone or in combination with other antiretrovirals for the treatment of HIV-1 infection.

In addition, tenofovir disoproxil is available in combination with emtricitabine (under the brand name Truvada) for use as pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents weighing ≥ 35kg to reduce the risk of sexually-acquired HIV-1 infection.

Associated Conditions: Chronic Hepatitis B Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

Phase 2

Not yet recruiting

Conditions: Chronic Hepatitis B Infection

Interventions: Drug: ALG-000184
Drug: TDF

First Posted Date: 2025-05-09

Last Posted Date: 2025-05-09

Lead Sponsor: Aligos Therapeutics

Target Recruit Count: 200

Registration Number: NCT06963710

Optimizing Treatment for Patients with Juvenile Idiopathic Arthritis in Sustained Remission: the MOVE-JIA Trial

Phase 4

Recruiting

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Methotrexate
Drug: TNF Inhibitor

First Posted Date: 2024-10-22

Last Posted Date: 2025-03-24

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 150

Registration Number: NCT06653634

Locations: 🇳🇴
Drammen Hospital, Drammen, Norway
🇳🇴
Haukeland University Hospital, Bergen, Norway
🇳🇴
Hospital of Southern Norway Hospital Trust, Kristiansand, Norway

and more 4 locations

Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital

Not yet recruiting

Conditions: Inflammatory Bowel Disease (IBD)
Spondylarthropathies
TNF-alpha Inhibitors

Interventions: Drug: TNF inhibitors
Drug: conventional ibd medical treatment

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Mohamed Nasr

Target Recruit Count: 100

Registration Number: NCT06601595

Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia

Recruiting

Conditions: Hepatitis B

Interventions: Drug: Tenofovir Disoproxil Fumarate

First Posted Date: 2024-09-06

Last Posted Date: 2024-09-12

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 4500

Registration Number: NCT06586983

Locations: 🇪🇹
Addis Ababa University, Addis Ababa, Ethiopia

Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B

Completed

Conditions: Chronic Hepatitis B
Hepatic Steatosis

Interventions: Diagnostic Test: Transient elastography
Drug: Tenofovir Disoproxil Fumarate

First Posted Date: 2024-08-27

Last Posted Date: 2024-08-27

Lead Sponsor: Yaşar Bayındır, MD

Target Recruit Count: 70

Registration Number: NCT06573190

Locations: 🇹🇷
Guven Hospital, Ankara, Turkey

Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease

Phase 1

Recruiting

Conditions: Parkinson Disease

Interventions: Drug: Tenofovir Disoproxil Fumarate

First Posted Date: 2024-04-10

Last Posted Date: 2025-02-17

Lead Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Target Recruit Count: 60

Registration Number: NCT06356662

Locations: 🇨🇳
Guohua Zhao, Hangzhou, Zhejiang, China

Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Ozanimod
Drug: TNF Inhibitor
Drug: Steroids
Drug: Vedolizumab
Drug: Ustekinumab

First Posted Date: 2023-01-27

Last Posted Date: 2023-12-06

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 240

Registration Number: NCT05702879

Locations: 🇨🇭
University Hospital Bern Inselspital, Bern, Switzerland

Replicor Compassionate Access Program

Conditions: Viral Hepatitis B
Viral Hepatitis D
Cirrhosis, Liver
Decompensated Cirrhosis
Ascites Hepatic
Varices, Esophageal
Hepatocellular Carcinoma